Marcelo Vailati Negrao

32PUBLICATIONS
274CO-AUTHORS
Molecular targetsTumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Oct 02, 2026
SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.

|Apr 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

|Dec 13, 2025
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.

Martin Reck, Shun Lu, Kenneth J O'Byrne

|Dec 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer.

Hui Li, Lingzhi Hong, Pedro Rocha

|Oct 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.

Melissa L Johnson, Egbert F Smit, Enriqueta Felip

|Aug 27, 2025
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Federica Pecci, Hui Li, Alessandro Di Federico

Pageof 6

Frequent Collaborators

17 joint publications

Jianjun Zhang

16 joint publications

John Victor Heymach

13 joint publications

Don L Gibbons

12 joint publications

Jack Lee